(60 days)
The Micrus Microcoil Delivery System is intended for endovascular embolization of intracranial aneurysms.
The Micrus Cashmere-Cerecyte and Cashmere-SR Microcoil Systems each consists of an embolic coil (“Microcoil”) attached to Device Positioning Unit (DPU) (single use, sterile)
This document describes a 510(k) premarket notification for the Micrus Microcoil Delivery System and does not contain information about acceptance criteria or a study proving that a device meets acceptance criteria. Instead, it focuses on demonstrating substantial equivalence to predicate devices, which is a different regulatory pathway.
Therefore, I cannot fulfill the request to provide information based on acceptance criteria and a study from the provided text.
Here's why the prompt cannot be answered with the given text:
- Type of Submission: The document is a "Summary of Safety and Effectiveness" for a 510(k) submission. 510(k) submissions typically demonstrate substantial equivalence to a legally marketed predicate device, rather than proving a device meets specific, predefined acceptance criteria through a clinical or performance study.
- Content Focus: The text explicitly states, "Based upon the design, materials, function, intended use, comparison with currently marketed devices and the non-clinical testing performed by Micrus Endovascular Corporation, it is concluded that the Micrus Cashmere-Cerecyte and Cashmere-SR Microcoil Systems are substantially equivalent to the predicate devices in safety and effectiveness." This indicates that the "study" was primarily a comparison to existing devices and non-clinical testing, not a formal study with acceptance criteria being met.
- Missing Information: The document lacks the detailed information requested in the prompt, such as:
- Specific acceptance criteria values.
- Quantitative performance results for the new device against those criteria.
- Sample sizes for test sets, data provenance, ground truth establishment, expert information, adjudication methods, MRMC studies, or standalone algorithm performance.
- Training set details.
In summary, the provided text is a regulatory clearance document for a medical device based on substantial equivalence, not a detailed report of a study designed to meet specific acceptance criteria.
{0}------------------------------------------------
Summary of Safety and Effectiveness
| Submitter Name andAddress: | Micrus Endovascular Corp.821 Fox LaneSan Jose, CA 95131 | OCT 5 ° 2007 |
|---|---|---|
| Contact Name: | Patrick LeePhone: 408-433-1428Fax: 408-433-1585Email: plee@micruscorp.com | |
| Preparation Date: | August 3, 2007 | |
| Device Name andClassification: | Micrus Microcoil SystemCommon Name: Micrus “Cashmere-Cerecyte” and “Cashmere-SR”Classification Name: Device, Neurovascular EmbolizationRegulatory Class II | |
| Predicate Devices: | Micrus Cashmere-14 Microcoil, 510(k) no.K063653Micrus Cerecyte Microcoil, 510(k) no. K033813 | |
| Device Description: | The Micrus Cashmere-Cerecyte and Cashmere-SR MicrocoilSystems each consists of an embolic coil (“Microcoil”) attached toDevice Positioning Unit (DPU) (single use, sterile) | |
| Device Intended Use | The Micrus Microcoil Delivery System is intended for endovascularembolization of intracranial aneurysms. |
Comparison to Predicate Devices:
The Micrus Cashmere-Cerecyte and Cashmere-SR Microcoil Systems have shown substantial equivalence to the Micrus Cashmere-14 Microcoil System and Micrus Cerecyte Microcoil System in terms of intended use, design, material of construction, implant dimensions including wire dimensions, pitch, coil stiffness, and coil length. The Cashmere-Cerecyte and Cashmere-SR microcoils use the same method and material of construction, packaging, and sterilization method as its predicates. The modification has not altered the fundamental technology of the sponsor's predicate device
Conclusion:
Based upon the design, materials, function, intended use, comparison with currently marketed devices and the non-clinical testing performed by Micrus Endovascular Corporation, it is concluded that the Micrus Cashmere-Cerecyte and Cashmere-SR Microcoil Systems are substantially equivalent to the predicate devices in safety and effectiveness.
{1}------------------------------------------------
Image /page/1/Picture/12 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized eagle with its wings spread, symbolizing protection and service. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The seal is simple and monochromatic.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Micrus Endovascular Corporation % Mr. Patrick Lee Regulatory Affairs Specialist 821 Fox Lane San Jose, California 95131
OCT 5 2007
Re: K072173
Trade/Device Name: Micrus Microcoil Delivery System Regulation Number: 21 CFR 882.5950 Regulation Name: Neurovascular embolization device Regulatory Class: II Product Code: HCG Dated: September 06, 2007 Received: September 07, 2007
Dear Mr. Lee:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{2}------------------------------------------------
Page 2 - Mr. Patrick Lee
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely vours.
Barbara Buchner
dos
Mark N. Melk Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Page 3 - Mr. Patrick Lee
cc: HFZ-401 DMC HFZ-404 510(k) Staff HFZ-410 Division D.O. f/t:TRN:kxl:10-04-07
.OC Numbers:
| Division of Enforcement A | 240-276-0115 |
|---|---|
| Dental, ENT and Ophthalmic Devices Branch | 240-276-0115 |
| OB/GYN, Gastro. & Urology Devices Branch | 240-276-0115 |
| General Hospital Devices Branch | 240-276-0115 |
| General Surgery Devices Branch | 240-276-0115 |
| Division of Enforcement B | 240-276-0120 |
| Cardiovascular & Neurological Devices Branch | 240-276-0120 |
| Orthopedic, Physical Medicine & Anesthesiology Devices Br | 240-276-0120 |
:
:
.
{4}------------------------------------------------
Indications for Use
510(k) Number (if known): _
Micrus Microcoil Delivery System Device Name: _
Indications For Use:
The Micrus Microcoil Delivery System is intended for endovascular embolization of intracranial aneurysms.
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Barbara Mann
(Division Sign-Off)
Division of General, Restorative, and Neurological Devices
510(k) Number K072173
Page 1 of 1
§ 882.5950 Neurovascular embolization device.
(a)
Identification. A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral ateriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in other vascular applications are also not included in this classification, see § 870.3300.(b)
Classification. Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 882.1(e).